Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM4A | O75164 | 11/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 11/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.41 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31370514 | 0.86 | PAOX (0.53) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL29256117 | 0.84 | CYP2C9 (0.48) | CYP2C9CYP2C19KDM4AKDM4CANPEP | |
| SCHEMBL27293107 | 0.81 | PAOX (0.47) | CYP2C9CYP2C19ANPEPPRMT3CARM1 | |
| SCHEMBL16158922 | 0.80 | MVD (0.42) | CYP2C19KDM4CKDM5AKDM7APHF8 | |
| SCHEMBL31370382 | 0.80 | CTH (0.34) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL27293082 | 0.79 | CYP2C9 (0.43) | CYP2C9CYP2C19ANPEPPRMT3CARM1 | |
| SCHEMBL28709277 | 0.79 | CYP2C9 (0.48) | CYP2C9CYP2C19ANPEPPRMT3CARM1 | |
| SCHEMBL19214722 | 0.77 | KDM4E (0.47) | CYP2C19KDM4CKDM5AKDM4EPAOX | |
| SCHEMBL1844564 | 0.77 | PRMT3 (0.42) | CYP2C9CYP2C19ANPEPPRMT3CARM1 | |
| SCHEMBL25356442 | 0.77 | MEN1 (0.35) | KDM7APHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121600-B1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-18 | — | — | EP | claimed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | claimed |
| EP-2121600-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2009-11-25 | — | — | EP | claimed |
| WO-2008099000-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-21 | — | — | WO | claimed |
| CN-117917989-A | Use of a reversible metal electrodeposited electrolyte with pH-adjustable, dynamic glass element with high opacity and excellent rest stability, and electrolyte useful therefor | 代表内华达大学雷诺分校的内华达高等教育系统董事会 | 2024-04-23 | — | — | CN | disclosed |
| WO-2023133645-A1 | RADIOLABELED COMPOUNDS FOR IMAGING OF FIBROBLAST ACTIVATION PROTEIN (FAP) AND TREATMENT OF FAP-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-07-20 | — | — | WO | disclosed |
| CN-110357863-B | Triazine double aromatic ring derivative epidermal growth factor inhibitor and preparation method and application thereof | 药雅科技(上海)有限公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-111777599-A | Quinazoline, pyridopyrimidine or bipyrimidine bi-aromatic ring derivative EGFR inhibitor and preparation method and application thereof | 药雅科技(上海)有限公司 | 2020-10-16 | — | — | CN | disclosed |
| CN-111574503-A | Pyrimidine double aromatic ring derivative epidermal growth factor inhibitor and preparation method and application thereof | 药雅科技(上海)有限公司 | 2020-08-25 | — | — | CN | disclosed |
| US-10428043-B2 | Green oxidation catalytic system | TRUSTEES OF BOSTON UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| US-9518092-B2 | Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity | POLYPHOR LTD. (CH) | 2016-12-13 | — | — | US | disclosed |
| WO-2008087189-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087186-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087188-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087187-A1 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| US-20070078079-A1 | Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity | POLYPHOR LTD. (CH) | 2007-04-05 | — | — | US | disclosed |
| EP-1622931-A1 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY | Polyphor AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096840-A1 | TEMPLATE- FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY | POLYPHOR AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| US-5366954-A | Bathing in storage solution to extend bloom life | EPITOPE, INC. (US) | 1994-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078079-A1 | Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity | CXCR4, CXCL12, CCR5 | CYP2C9 4787/4885CYP2C19 4485/4885KDM4A 4648/4885 |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | CYP2C9 471/4885CYP2C19 700/4885KDM4A 692/4885 |
| US-10428043-B2 | Green oxidation catalytic system | TKT, OGDH, SOD1 | CYP2C9 363/4885CYP2C19 931/4885KDM4A 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.